Overview

Anti CD19 Gene Therapy for B-cell Lymphoma

Status:
RECRUITING
Trial end date:
2029-12-31
Target enrollment:
Participant gender:
Summary
This is an open label, single-site, dose-escalation study in up to 18 participants with treatment of relapsed/refractory B-cell lymphoma. This study aims to evaluate the safety and efficacy of the treatment with an Anti- CD19 gene injection
Phase:
NA
Details
Lead Sponsor:
Anhui Provincial Hospital